Market Research Logo

Chronic Heart Failure - Pipeline Review, H2 2015

Chronic Heart Failure - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Chronic Heart Failure - Pipeline Review, H2 2015’, provides an overview of the Chronic Heart Failure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chronic Heart Failure Overview
Therapeutics Development
Pipeline Products for Chronic Heart Failure - Overview
Pipeline Products for Chronic Heart Failure - Comparative Analysis
Chronic Heart Failure - Therapeutics under Development by Companies
Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes
Chronic Heart Failure - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Chronic Heart Failure - Products under Development by Companies
Chronic Heart Failure - Products under Investigation by Universities/Institutes
Chronic Heart Failure - Companies Involved in Therapeutics Development
Amgen Inc.
AnGes MG, Inc.
ARCA biopharma, Inc.
Bayer AG
Bial - Portela & Ca, S.A.
Caladrius Biosciences, Inc.
Capricor Therapeutics, Inc.
Celyad SA
Jiangsu Hengrui Medicine Co., Ltd.
Juventas Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Les Laboratoires Servier SAS
Mast Therapeutics, Inc.
Mesoblast Limited
Novartis AG
Pfizer Inc.
PhaseBio Pharmaceuticals, Inc.
Sanofi
Stemedica Cell Technologies, Inc.
Vichem Chemie Research Ltd.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Chronic Heart Failure - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(sacubitril + valsartan) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aliskiren fumarate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-1067197 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIA-51058 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C3BSCQR-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carvedilol phosphate ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cenderitide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-373280 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
finerenone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
furosemide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ivabradine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MPC-150IM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neucardin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omecamtiv mecarbil MR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PB-1046 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-296968 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
serelaxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Chronic Heart Failure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vepoloxamer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vericiguat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Heart Failure - Recent Pipeline Updates
Chronic Heart Failure - Dormant Projects
Chronic Heart Failure - Discontinued Products
Chronic Heart Failure - Product Development Milestones
Featured News & Press Releases
Nov 10, 2015: Novartis heart failure medicine Entresto substantially cuts 30-day hospital readmissions, new post-hoc analysis shows
Nov 09, 2015: Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions
Nov 08, 2015: Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015
Nov 06, 2015: Latest Clinical Data of Vericiguat To Be Presented at Late-Breaking-Clinical-Trial Session at AHA
Nov 04, 2015: scPharmaceuticals Announces Positive Results from Pivotal Trial of its Novel Subcutaneous Furosemide Formulation in Patients with Heart Failure
Nov 02, 2015: Amgen To present abstracts on Corlanor At American Heart Association Scientific Sessions 2015
Oct 27, 2015: Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
Oct 26, 2015: Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure
Sep 29, 2015: Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
Sep 28, 2015: Mast Announces Presentation of Results of Nonclinical Study of Vepoloxamer in Chronic Heart Failure at the HFSA's Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chronic Heart Failure, H2 2015
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Chronic Heart Failure - Pipeline by Amgen Inc., H2 2015
Chronic Heart Failure - Pipeline by AnGes MG, Inc., H2 2015
Chronic Heart Failure - Pipeline by ARCA biopharma, Inc., H2 2015
Chronic Heart Failure - Pipeline by Bayer AG, H2 2015
Chronic Heart Failure - Pipeline by Bial - Portela & Ca, S.A., H2 2015
Chronic Heart Failure - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Chronic Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2015
Chronic Heart Failure - Pipeline by Celyad SA, H2 2015
Chronic Heart Failure - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Chronic Heart Failure - Pipeline by Juventas Therapeutics, Inc., H2 2015
Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H2 2015
Chronic Heart Failure - Pipeline by Mast Therapeutics, Inc., H2 2015
Chronic Heart Failure - Pipeline by Mesoblast Limited, H2 2015
Chronic Heart Failure - Pipeline by Novartis AG, H2 2015
Chronic Heart Failure - Pipeline by Pfizer Inc., H2 2015
Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015
Chronic Heart Failure - Pipeline by Sanofi, H2 2015
Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Chronic Heart Failure - Pipeline by Vichem Chemie Research Ltd., H2 2015
Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H2 2015
Chronic Heart Failure - Dormant Projects, H2 2015
Chronic Heart Failure - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Chronic Heart Failure, H2 2015
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report